EXTEND (Eltrombopag Extended Dosing Study)
clinical trial
Press Enter · cited answer in seconds
0 sources
EXTEND (Eltrombopag Extended Dosing Study)
Summary
EXTEND (Eltrombopag Extended Dosing Study) is a clinical trial[1].
Key Facts
- EXTEND (Eltrombopag Extended Dosing Study) is located in Hong Kong[2].
- EXTEND (Eltrombopag Extended Dosing Study) is in the country of Australia[3].
- EXTEND (Eltrombopag Extended Dosing Study) is in the country of Austria[4].
- EXTEND (Eltrombopag Extended Dosing Study) is in the country of Canada[5].
- EXTEND (Eltrombopag Extended Dosing Study) is in the country of Czech Republic[6].
- EXTEND (Eltrombopag Extended Dosing Study) is in the country of Denmark[7].
- EXTEND (Eltrombopag Extended Dosing Study) is in the country of Finland[8].
- EXTEND (Eltrombopag Extended Dosing Study)'s instance of is recorded as clinical trial[9].
- EXTEND (Eltrombopag Extended Dosing Study)'s start time is recorded as +2006-06-30T00:00:00Z[10].
- EXTEND (Eltrombopag Extended Dosing Study)'s end time is recorded as +2015-07-31T00:00:00Z[11].
- EXTEND (Eltrombopag Extended Dosing Study)'s sponsor is recorded as Novartis[12].
- EXTEND (Eltrombopag Extended Dosing Study)'s main subject is recorded as thrombocytopenia[13].
- EXTEND (Eltrombopag Extended Dosing Study)'s main subject is recorded as purpura[14].
- EXTEND (Eltrombopag Extended Dosing Study)'s number of participants is recorded as {'unit': '1', 'amount': '+302'}[15].
- EXTEND (Eltrombopag Extended Dosing Study)'s title is recorded as EXTEND (Eltrombopag Extended Dosing Study): An Extension Study of Eltrombopag Olamine (SB-497115-GR) in Adults, With Idiopathic Thrombocytopenic Purpura (ITP), Previously Enrolled in an Eltrombopag Study.[16].
- EXTEND (Eltrombopag Extended Dosing Study)'s short name is recorded as EXTEND[17].
- EXTEND (Eltrombopag Extended Dosing Study)'s minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}[18].
- EXTEND (Eltrombopag Extended Dosing Study)'s ClinicalTrials.gov ID is recorded as NCT00351468[19].
- EXTEND (Eltrombopag Extended Dosing Study)'s clinical trial phase is recorded as phase III clinical trial[20].
- EXTEND (Eltrombopag Extended Dosing Study)'s research site is recorded as Novartis[21].
- EXTEND (Eltrombopag Extended Dosing Study)'s study type is recorded as interventional study[22].